pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$ZLABZai Lab Ltd

$ZLAB22.11-6.03%
Shanghai, CNupdated 9h ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
3
marketed
0
phase 3
1
catalysts ytd
1
approvals ytd
0
recalls ytd
0

Pipeline(3)

pipeline depth3 products
Preclinical: 1Phase 1: 1Phase 3: 1
1Preclinical1Phase 11Phase 3
Phase 3
zocilurtatug pelitecan
Small-Cell Lung Cancer
Phase 1
ZL-6201
Breast Cancer
Preclinical
ZL-1311
Gastric Cancer

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Nov 5, 2026
earnings
$ZLAB22.11-6.03%
14d ago
Zai Lab Ltd earnings
Zai Lab Ltd
→
view all catalysts →
🐶 Hiring Signal
No open roles indexed yet — view Zai Lab Ltd jobs →

News

  • Molecular Partners to lay off up to 44% of workforce in radiotherapy pivot
    Molecular Partners plans to lay off up to 44% of its staff as it focuses its declining cash reserves on a radiotherapeutic pipeline led by an early-phase small cell lung cancer drug candidate.
    fiercebiotech · 20d ago
  • ESMO 2026: Amgen’s Imdelltra slashes death risk by nearly 60% in small cell lung cancer
    When used alongside AstraZeneca’s Imfinzi, the bispecific T cell engager Imdelltra extended survival by eight months versus Imfinzi alone in Phase 3 study testing the combo in a first-line maintena…
    biospace · 23d ago
  • #ESMO26 regular abstracts featuring Zai Lab, GSK, Merck and more
    The last time the ESMO congress was in Madrid, a presentation on first-line data in bladder cancer drew a rapturous standing ovation. Contenders that might draw the same reception include hotly ant…
    endpoints · 1mo ago
  • Merck, Daiichi end plans to seek speedy approval of lung cancer ADC
    The FDA indicated that the data generated so far wouldn’t support an accelerated clearance of “I-DXd,” a setback that erases an edge Merck and Daiichi had over multiple fast-moving competitors.
    biopharma_dive · 1mo ago
identifiers
ticker
$ZLAB
SEC CIK
0001704292
country
CN
source
sec_tickers
top tags
Oncology3Breast Cancer1NSCLC1
mentioned in
4news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 10m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?